Envista's (NVST) "Hold" Rating Reiterated at Needham & Company LLC

Envista (NYSE:NVST - Get Free Report)'s stock had its "hold" rating reiterated by research analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports.

Other equities analysts also recently issued reports about the stock. Piper Sandler increased their price target on shares of Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Jefferies Financial Group raised their target price on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a research note on Thursday, January 23rd. Wells Fargo & Company upped their price target on Envista from $20.00 to $21.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 6th. Morgan Stanley raised their price objective on Envista from $19.00 to $20.00 and gave the company an "equal weight" rating in a research report on Thursday, February 6th. Finally, Mizuho assumed coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $20.18.

Envista Trading Down 4.8 %

Shares of NYSE NVST traded down $0.89 during trading hours on Thursday, hitting $17.55. The company's stock had a trading volume of 3,168,325 shares, compared to its average volume of 2,287,146. The business has a 50-day simple moving average of $20.22 and a 200-day simple moving average of $19.70. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -2.70, a P/E/G ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista has a 12 month low of $15.15 and a 12 month high of $23.00.

Remove Ads

Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Huntington National Bank increased its stake in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company's stock worth $38,000 after buying an additional 949 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after acquiring an additional 1,638 shares in the last quarter. GAMMA Investing LLC grew its stake in Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock worth $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Envista during the 4th quarter worth $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Envista during the 4th quarter worth $86,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.